<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-18T00:07:12Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/12787" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/12787</identifier><datestamp>2025-09-30T02:08:19Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study</dc:title>
   <dc:creator>IACOBONI, GLORIA</dc:creator>
   <dc:creator>CABALLERO GONZÁLEZ, ANA CAROLINA</dc:creator>
   <dc:creator>Delgado Serrano, Javier</dc:creator>
   <dc:creator>BASTOS, MARIANA</dc:creator>
   <dc:creator>Martínez-Cibrian, Nuria</dc:creator>
   <dc:creator>Barba, Pere</dc:creator>
   <dc:creator>Navarro Garces, Victor</dc:creator>
   <dc:contributor>Institut Català de la Salut</dc:contributor>
   <dc:contributor>[Bastos‐Oreiro M] Hematology Department, Hospital General Universitario Gregorio Marañon, Instituto de investigación sanitaria Gregorio Marañon, Madrid, Spain.  [Iacoboni G] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.  [Garcés VN, Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain.  [Caballero AC] Department d’hematologia, Hospital Sant Pau, Barcelona, Spain.  [Martínez N] Servei d'Hematologia, Hospital Clínic, Barcelona, Spain.  [Delgado J] Hematology Department, Virgen del Rocío, Sevilla, Spain</dc:contributor>
   <dc:contributor>Vall d'Hebron Barcelona Hospital Campus</dc:contributor>
   <dc:subject>Avaluació de resultats (Assistència sanitària)</dc:subject>
   <dc:subject>Cèl·lules B - Tumors - Immunoteràpia</dc:subject>
   <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome</dc:subject>
   <dc:subject>DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse</dc:subject>
   <dc:subject>Other subheadings::Other subheadings::Other subheadings::/drug therapy</dc:subject>
   <dc:subject>DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression</dc:subject>
   <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive</dc:subject>
   <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento</dc:subject>
   <dc:subject>ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso</dc:subject>
   <dc:subject>Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia</dc:subject>
   <dc:subject>ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::progresión de la enfermedad</dc:subject>
   <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva</dc:subject>
   <dc:description>T-cell therapy; Large B-cell lymphoma; Disease progression</dc:description>
   <dc:description>Terapia de células T; Linfoma de células B grandes; Progresión de la enfermedad</dc:description>
   <dc:description>Teràpia de cèl·lules T; Limfoma de cèl·lules B grans; Progressió de la malaltia</dc:description>
   <dc:date>2025-03-19T11:45:27Z</dc:date>
   <dc:date>2025-03-19T11:45:27Z</dc:date>
   <dc:date>2025-02-04</dc:date>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:identifier>Bastos-Oreiro M, Iacoboni G, Garcés VN, Caballero AC, Martínez N, Delgado J, et al. Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study. HemaSphere. 2025 Feb;9(2):e70077.</dc:identifier>
   <dc:identifier>2572-9241</dc:identifier>
   <dc:identifier>http://hdl.handle.net/11351/12787</dc:identifier>
   <dc:identifier>10.1002/hem3.70077</dc:identifier>
   <dc:identifier>39906687</dc:identifier>
   <dc:identifier>001413884400001</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>HemaSphere;9(2)</dc:relation>
   <dc:relation>https://doi.org/10.1002/hem3.70077</dc:relation>
   <dc:rights>Attribution-NonCommercial-NoDerivatives 4.0 International</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>Wiley</dc:publisher>
   <dc:source>Scientia</dc:source>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>